During an interview with IdeaMensch, Foresite Capital CEO Jim Tananbaum revealed insight into his personal and professional career within the healthcare and financial industries. Jim is a firm believer in healthcare innovation and its ability to yield surprisingly enduring value and long-term impact.
When asked about the inspiration behind Foresite Capital, Jim said that it was a result of his 25-year experience in investment strategy and healthcare entrepreneurship. He said that the real secret was healthcare innovation and making strategic investments. He added that success was also reliant on collecting and digesting relevant industry information.
Jim revealed that he relies heavily on competent management teams. He not only spends his days working in tandem with his team and industry networks but also spends time with his family. He stated that he brings ideas to life through engaging other healthcare leaders. Jim focuses on the investment and business side of healthcare and believes in team synergy. He also said that given the opportunity to start over, he would take more risks and believe in himself.
According to INC42, Jim Tananbaum is the founder and present CEO of Foresite Capital. Jim created Foresite back in 2011 as a private equity firm (healthcare dedicated) specializing in the identification of emerging healthcare leaders. It then supplies these leaders with capital, information, and networks allowing them to grow to profitability. He studied electrical engineering, computer science and math at Yale University. He also holds an M.S. degree from Massachusetts Institute of Technology as well as an M.B.A. and M.D. from Harvard University.
Apart from Foresite Capital, Jim Tananbaum co-founded two healthcare investment practices as well as two leading biopharmaceutical companies. He founded GelTex Pharmaceuticals whose lead drug, Renagel, achieved an annual revenue of over $200 million in 1998. Today, the drug produces almost $1 billion in revenue annually. Visit pelotontherapeutics for more details.
Jim also co-founded Theravance, Inc., and headed the company as CEO. He also completed a spin-off company called Theravance Biopharma, Inc. The two companies enjoy a combined market capitalization of about $3.2 billion. Jim Tananbaum is one of the founding partners of Prospect Venture Partners. He was also one of the partners at Sierra Ventures. Other investments that he has been involved in include Amira Pharmaceuticals, Amerigroup, Healtheon, and Jazz Pharmaceuticals.